← Back to ALGS

Aligos Therapeutics, Inc. - Common stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 06/08/2026Mar 2026Filed 06/08/2026Sep 2025Filed 06/11/2025Jun 2025Filed 06/08/2026Mar 2025Filed 06/08/2026Sep 2024Filed 06/11/2025Jun 2024Filed 06/11/2025Mar 2024Filed 06/11/2025
$0$2.8$0.7$1$0.3$1.3$1.1$0.7
−$1.5−$23−$32−$16$43−$19$5.1−$35
−$0.14−$2.21−$3.04−$1.53−$2.11−$3.07$0.81−$5.58
101010108.76.36.36.2

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.